Sagility India Limited has informed the Exchange about Investor Presentation
Date: May 14, 2025
To, The Manager Listing Department National Stock Exchange (NSE) Exchange Plaza, 5th Floor Plot No. C/1, G-Block Bandra-Kurla Complex Bandra (E), Mumbai - 400 051 Symbol: SAGILITY
Dear Sir/Ma’am,
To, The Manager Listing Department Bombay Stock Exchange (BSE) Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001 Scrip Code:544282
Subject: Submission of Investor Presentation to be made to investors on May 15, 2025, pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
In continuation to our letter dated May 09, 2025, we are enclosing herewith the presentation to be shared with investors regarding the audited financial results of the Company for quarter and year ended 31st March 2025 at 8:30AM (IST).
The details are also being made available on the Company’s website https://sagilityhealth.com/
This is for your kind information and record.
Thanking You,
For Sagility India Limited
Satishkumar Sakharayapattana Seetharamaiah Company Secretary & Compliance Officer M. No: A16008
Encl: a/a
Sagility India Limited (Formerly Sagility India Private Limited) Registered Office - No. 23 & 24, AMR Tech Park, Building 2A, First Floor Hongasandara Village, Off Hosur Road, Bommanahalli, Bengaluru – 560068 Karnataka India Corporate Identity Number: L72900KA2021PLC150054 Tel. No.: 080-71251500, Website: www.SagilityHealth.com
May 15, 2025
Investor Deck – FY25
Safe Harbour
Certain statements in this release concerning Sagility’ future growth prospects may be seen as forward- looking statements, which involve a number of risks and uncertainties that could cause the actuals to differ materially from such statements. Sagility does not undertake to update any such statement that may have been made from time to time by or on behalf of the company..
2
Key Highlights
FY25 Highlights
Q4 FY25 Highlights
► FY25 Revenue at ₹55,699 million, grew by ₹8,164 million Y-o-Y
► Revenue in Q4 at ₹ 15,685 million grew by ₹2,853 million Y-o-Y (corresponding
(corresponding to 17.2% growth Y-o-Y and 14.9% at constant currency.
to 22.2% growth Y-o-Y and 17.7% at constant currency.
► Adjusted EBITDA (excl Other Income) at ₹14,685 million, grew by ₹3,249
► Adjusted EBITDA (excl Other Income) at ₹4,042 million, grew by ₹899 million Y-
million Y-o-Y (corresponding to 28.4% growth Y-o-Y )
o-Y (corresponding to 28.6% growth Y-o-Y )
► Adjusted PAT at ₹8.107 million, grew by ₹ 2,211 million Y-o-Y (corresponding
► Adjusted PAT at ₹2,398 million, grew by ₹747 million Y-o-Y (corresponding to
to 37.5% growth Y-o-Y )
45.2% growth Y-o-Y )
Key Business Highlights
► FY25 concluded with robust year-on-year growth, largely fueled by our tenured existing clients and logos won over the last couple of years. Total Q-o-Q growth of
7.9% in INR and 5.7% in constant currency was fueled by acquisition of Broadpath in Q4.
► Together with tech- and transformation-led services—powered by automation, analytics, and GenAI, and our consulting services, we are gaining strong traction with
clients, further enhancing our reputation as a trusted strategic and advisory partner.
► Recent acquisition of BroadPath has the potential to unlock additional opportunities in several mid-market clients of Broadpath ; targeted cross-sell initiatives planned
for FY26
► Operations remain robust, driven by strong performance across key metrics
► People: Global headcount stands at 39,409 as of Mar 2024.
► 4,365 employees added during FY25 (12.5% Y-o-Y growth in headcount); Attrition at 27.5%*
► Recognitions: Major Contender in the Everest Group Payment Integrity Solutions PEAK Matrix® Assessment 2025; Major Contender in Healthcare Payer Business
Process as a Service (BPaaS) – Solutions PEAK Matrix® Assessment 2024
* Voluntary attrition considering employees who were employees for more than 90 days (%) on an annualized basis exclude BroadPath
3
KPIs
KPI
Q4'25
Q3'25
Q4'24
YoY%
FY'25
FY'24
YoY%
Revenue from Operation (in INR Million)
15,685
14,531
12,832
22.2%
55,699
47,536
17.2%
Revenue by Vertical Split
By Payer %
By Provider %
89.7%
89.3%
90.8%
89.4%
90.3%
10.3%
10.7%
9.2%
10.6%
9.7%
Growth in revenue from operation (%)
22.2%
15.3%
17.2%
12.7%
Adjusted EBITDA (in INR Million)
Adjusted EBITDA %
Adjusted PAT (in INR Million)
Adjusted PAT %
4,143
26.4%
2,398
15.3%
4,567
31.4%
2,626
18.1%
3,188
30.0%
15,248
11,715
30.2%
24.8%
1,651
12.9%
27.4%
24.6%
45.2%
8,107
5,896
37.5%
14.6%
12.4%
Total Number of Employees
39,409
39,595
35,044
12.5%
39,409
35,044
12.5%
Voluntary attrition rate* (%)
32.5%
21.8%
30.4%
27.5%
27.2%**
*considering employees who were employees for more than 90 days (%) on an annualized basis. **FY attrition rate exclude BroadPath
4
Annual KPI’s
KPI
Number of Client groups*
Active
Number of new client addition (Gross)
Client groups contribution to revenues
Top 3 Client %
Top 5 Client %
Top 10 Client %
Number of Million-dollar client groups
Number of clients contributing more than US$20 million
Number of clients contributing to US$5 - US$20 million
Number of clients contributing to US$1 - US$5 million
Number of clients contributing less than US$1 million
Delivery sites
Number of delivery sites
New site addition (Gross)
FY'25
FY'24
FY’23
75
38
66.2%
77.9%
90.5%
7
6
12
50
33
10
44
13
68.3%
79.2%
91.4%
5
7
12
20
30
4
35
7
72.4%
80.6%
90.7%
4
7
12
12
27
2
* Client groups comprise client entities together with their affiliates.
5
Financial Highlights
Highlights
Strong FY25 Performance
FY25 Financial Highlights
Q4 FY25 Financial Highlights
► FY25 revenue stood at ₹55,699 Million ($658.3 M)
► Q4’25 revenue stood at ₹15,685 Million ($181.8 M)
► 17.2% growth Y-o-Y (14.9% at constant currency )
► 22.2% growth Y-o-Y (17.7% at constant currency ) ► 7.9% growth Q-o-Q (5.7% at constant currency)
► Adjusted EBITDA (excl OI) at ₹14,685 Million ($173.6 M)
► Adjusted EBITDA (excl OI) at ₹4,042 Million ($46.8 M)
► Adjusted EBITDA Margin : 26.4% ► 28.4% growth Y-o-Y
► Adjusted PAT at ₹8,107 Million ($95.8 M) ► Adjusted PAT Margin: 14.6% ► 37.5% growth Y-o-Y;
► OCF ₹12,141 Million ($ 143.5 M) ► 89.7% of EBITDA
► Adjusted EBITDA Margin : 25.8% ► 28.6% growth Y-o-Y;
► Adjusted PAT at ₹2,398 Million ($27.8 M) ► Adjusted PAT Margin : 15.3 % ► 45.2% growth Y-o-Y
► OCF ₹3,009 Million ($34.8 M) ► 78.5% of EBITDA
7
Quarter wise performance
₹15.0
₹14.0
Headcount (‘000)
₹13.0
₹12.0
₹11.0
4 2 Y F
₹10.0
₹9.0
33.5
36.5
₹11.2
12.8%
₹10.9
11.5%
Q1 FY24
Q2 FY24
36.6
₹12.6
12.4%
Q3 FY24
Revenue INR B
Adjusted PAT %
Headcount (‘000)
35.8
₹17.0
₹16.0
₹15.0
₹14.0
5 2 Y F
₹13.0
₹12.0
₹11.0
₹10.0
₹9.0
₹12.2
11.8%
38.3
₹13.3
12.3%
39.6
₹14.5
18.1%
35.0
₹12.8
12.9%
Q4 FY24
39.4*
₹15.7
15.3%
40.0%
35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
40.0%
35.0%
30.0%
25.0%
20.0%
15.0%
10.0%
5.0%
0.0%
Q1 FY25
Q2 FY25
Q3 FY25
Q4 FY25
Revenue INR B
Adjusted PAT %
* Q4 FY 25 Headcount includes BroadPath Headcount of 1,083 (acquired in Q4 FY25)
Financial performance snapshot – Long Term
Revenue (INR Million)
₹42,184
FY24 YoY%
FY25 YoY%
12.7%
₹47,536
17.2%
₹55,699
Adjusted EBITDA * (INR Million)
FY24 YoY%
FY25 YoY%
11.3%
28.4%
Adjusted PAT (INR Million)
FY24 YoY%
FY25 YoY%
29.4%
37.5%
₹10,272
₹11,436
₹14,685
₹4,556
₹5,896
₹8,107
FY'23
FY'24
FY'25
FY'23
FY'24
FY'25
FY'23
FY'24
FY'25
Revenue ($M)
FY24 YoY%
FY25 YoY%
10.5%
14.9%
Adjusted EBITDA* ($M)
FY24 YoY%
FY25 YoY%
9.2%
25.9%
Adjusted PAT ($M)
FY24 YoY%
FY25 YoY%
27.0%
34.8%
$518.2
$572.9
$658.3
$126.2
$137.8
$173.6
$56.0
$71.1
$95.8
FY'23
FY'24
FY'25
FY'23
FY'24
FY'25
FY'23
FY'24
FY'25
*Adjusted EBITDA excluding other income
9
Financial performance snapshot – Q4 FY25
Revenue (INR Million)
Y-o-Y
22.2%
Q-o-Q
7.9%
Adjusted EBITDA* (INR Million)
Y-o-Y
28.6%
Q-o-Q
-2.1%
Adjusted PAT (INR Million)
₹12,832
₹14,531
₹15,685
₹3,143
₹4,127
₹4,042
₹1,651
Y-o-Y
45.2%
₹2,626
Q-o-Q
-8.7%
₹2,398
Q4'24
Q3'25
Q4'25
Q4'24
Q3'25
Q4'25
Q4'24
Q3'25
Q4'25
Y-o-Y
17.7%
Q-o-Q
5.7%
$181.8
Adjusted EBITDA* ($M)
Y-o-Y
23.8%
$48.9
Q-o-Q
-4.2%
$46.8
$172.0
$37.8
Adjusted PAT ($M)
$19.9
Y-o-Y
40.1%
$31.1
Q-o-Q
-10.6%
$27.8
Revenue ($M)
$154.4
Q4'24
Q3'25
Q4'25
Q4'24
Q3'25
Q4'25
Q4'24
Q3'25
Q4'25
*Adjusted EBITDA excluding other income
10
Financial Indicators
Adjusted EPS (in INR)
1.76
1.06
1.38
Adjusted ROCE %
54.9%
41.6%
47.0%
FY'23
FY'24
FY'25
FY'23
FY'24
FY'25
Cash Conversion (%)
82.0%
68.2%
87.2%
70.8%
89.7%
80.5%
FY'23
FY'24
FY'25
Net Debt
₹21,678
1.85x
₹25,000
₹22,863
2.19x
₹20,000
₹15,000
₹10,000
₹5,000
₹0
FY'23
FY'24
2.50
2.00
1.50
1.00
0.50
-
₹10,432
0.68x
FY'25
OCF %
FCF %
Net Debt (in INR Million)
Net Debt to Adjusted EBITDA
Adjusted EPS is Adjusted PAT divided by weighted average number of equity shares Adjusted ROCE is Adjusted PAT plus Interest cost divided by capital employed (Assets excluding goodwill and intangibles assets less current liabilities) Net Debt is Borrowing plus lease liabilities less Cash and Cash equivalent. Borrowing doesn’t include accrued interest
11
Q4 & FY25 Consolidated Financials
Amt in INR M
Particulars
Q4 FY25 Q3 FY25 Q4 FY24
YoY%
QoQ%
FY25
FY24
YoY%
Revenue from Operation
15,685
14,531
12,832
22.2%
7.9%
55,699
47,536
17.2%
Other Income
Employee benefits expense
Other expenses
Reported EBITDA
Adjusted EBITDA
Adjusted EBITDA %
101
440
46
9,741
8,620
7,995
2,212
1,988
1,764
563
279
34,989
29,376
7,731
7,278
3,832
4,362
3,119
22.9% -12.2%
13,542
11,160
21.3%
4,143
4,567
3,188
30.0%
-9.3%
15,248
11,715 30.2%
26.4%
31.4%
24.8%
27.4%
24.6%
Adjusted EBITDA excl. other income
4,042
4,127
3,143
28.6%
-2.1%
14,685
11,436 28.4%
Adjusted EBITDA excl. other income %
25.8%
28.4%
24.5%
Finance costs
298
302
429
Depreciation and amortisation expenses
1,143
1,162
1,760
26.4%
1,271
24.1%
1,851
4,669
6,892
Profit Before Tax
Tax Expenses
2,390
2,898
929
157.3% -17.5%
7,602
2,417 214.6%
564
729
127
2,211
134
Reported Profit After Tax
1,826
2,169
802 127.6% -15.8%
5,391
2,283 136.2%
EPS
Adjusted PAT
Adjusted PAT %
0.39
0.46
0.19 108.5% -15.8%
1.17
0.53 119.3%
2,398
2,626
1,651
45.2%
-8.7%
8,107
5,896 37.5%
15.3%
18.1%
12.9%
14.6%
12.4%
❖ Q4’25 Organic Revenue at INR 14,929 Mn (YoY% 16.3% and QoQ% 2.7%)
❖ FY’25 Organic Revenue at INR
54,943 Mn (YoY% 15.6%)
❖ Q4 Adj. EBITDA margin (excl. OI) is lower than Q3 due to (a) Change in revenue mix as BroadPath is onshore (b) Salary hikes made effective from Jan 25
❖ Dip in Q4 Reported EBITDA
margins due to above and lower other income and earnout for BroadPath
❖ Finance cost include interest cost on long-term borrowing from promoter and interest expenses on lease liabilities
Adjusted EPS (Basic and Diluted) (Rs)
0.51
0.56
0.39
33.0%
-8.7%
1.76
1.38 27.7%
12
Adjustments on EBITDA and PAT
Adj EBITDA Bridge: Q4 FY25
INR Million
₹3,832
₹207
₹104
₹4,143
Adj EBITDA Bridge: FY25
INR Million
₹13,542
₹571
₹1,134
₹15,248
Reported EBITDA
Adj A
Adj B
Adjusted EBITDA
Reported EBITDA
Adj A
Adj B
Adjusted EBITDA
Adj PAT Bridge: Q4 FY25
INR Million
₹1,826
₹151
₹104
₹317
₹2,398
Adj PAT Bridge: FY25
INR Million
₹5,391
₹418
₹1,163
₹8,107
₹1,134
Reported PAT
Adj A
Adj B
Adj C
Adjusted PAT
Reported PAT
Adj A
Adj B
Adj C
Adjusted PAT
Adj A - Earnouts under acquisition agreements and for PAT it is adjusted for tax Adj B - Share based payment awards ( non cash expenses for the company and not tax deductible) Adj C - Intangible assets Amortization is amortization of intangible assets acquired pursuant to carveout of healthcare business from the seller
13
Go Forward Positions
Amt in INR M
Particulars
Closing Debt position
Debt Repayment
Interest Payment
Share based Payment awards
Earnouts Cost - DCI / Birch/ BroadPath
Intangibles Amortisation
FY'25
FY'26
FY'27
FY'28
FY'29
8,020
2,490
751
1,134
571
1,588
5,670
2,350
535
250
494
5,670
285
146
5
78
40
1,795
1,785
1,771
1,698
• Numbers are based on the current visibility of management and are subject to change. Factors such as new loans, acquisitions, foreign exchange rate or changes in our share-
based payment award plan could impact the final figures Intangible Amortisation include amortization of intangible assets acquired pursuant to business combinations (includes DCI, Birch and BroadPath)
•
14
Balance Sheet as on 31st Mar’25
Amt in INR M
Particulars
Property, plant and equipment
Capital-work-in-progress
Right-of-use assets
Goodwill
Other intangible assets
Trade receivables and Unbilled
Cash and cash equivalents
Deferred tax assets (net)
Other Assets
Total Assets
Equity
Borrowings
Lease liabilities
Trade payables
Other financial liabilities
Deferred tax liabilities (net)
Other Liabilities
Total Liabilities
❖ Increase in Goodwill and Intangible driven
by BroadPath acquisition
❖ Intangibles of $16.5M created as a result of
BroadPath acquisition
❖ DSO (excl. BroadPath) of 79 days in Mar’25
against 85 days in Mar’24.
❖ Borrowings (Promoter Debt) reduction due
to conversion of loan into equity (in May’24) and repayment of debt.
❖ Reduction in Other financial liabilities
pertains to pending purchase consideration paid towards for healthcare business carveout in Jan 22
Mar’25
Mar'24
3,699
0
5,521
60,390
20,362
12,668
3,438
1,337
3,091
110,507
83,361
8,170
5,850
2,136
3,059
4,279
3,653
3,832
57
5,665
57,096
20,078
11,813
3,441
1,354
3,305
106,642
64,431
19,335
5,982
2,593
6,587
4,710
3,004
110,507
106,642
15
Cash Flow – FY25
Amt in INR M Particulars
Profit before tax for the period/ year
Adjustment for Non-Operating and Non-Cash items
Adjustment for working capital
Income taxes paid (net of refunds)
Net cash flows generated from operating activities (A) - OCF
Addition to Fixed Assets
Free Cash flow (FCF)
Cash paid for M&A (BroadPath)
Pending Purchase consideration paid for healthcare business carveout
Others*
FY’25
FY'24
7,602
6,982
(710)
(1,734)
12,141
(1,244)
10,896
(4,825)
(3,756)
184
2,417
8,693
(114)
(1,263)
9,733
(1,827)
7,905
(3,010)
147
❖ Non-Cash/Non-Operating Items includes Depreciation, Interest expenses, SAR, Unrealized Fx loss and Interest income
❖ Others include Proceeds from sale of fixed assets, Interest income and Proceeds from maturity of derivative assets/liabilities, (net)
Net cash flows (used in) investing activities (B)
(9,642)
(4,691)
Capital infused by promoter
IPO expense reimbursed
Repayment of borrowings and lease liabilities
Interest paid on borrowings and lease liabilities
Net cash flows (used in) financing activities (C)
Net increase/ (decrease) in cash and cash equivalents (A+B+C)
Cash and cash equivalents at the beginning of the year/period
Effect of movement in exchange rates on cash and cash equivalents
Cash and cash equivalents at the end of the year/ period
Net cash flows generated from operating activities % (OCF on Reported EBITDA)
Free Cash flow % (FCF on EBITDA)
3,708
72
(5,021)
(1,320)
(2,561)
(62)
3,441
58
3,438
89.7%
80.5%
0
(72)
(5,546)
(1,896)
(7,513)
(2,471)
5,853
60
3,441
87.2%
70.8%
16
Thank You